Keep up to date with our latest partnering deals and highlights

Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.

Wednesday, 3 April 2013
MedImmune, AstraZeneca’s biologics arm, acquires AlphaCore Pharma AstraZeneca today announced that MedImmune, its global biologics research and development arm, has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme.
Thursday, 21 March 2013
AstraZeneca appoints Marc Dunoyer as Executive Vice President, Global Portfolio & Product Strategy AstraZeneca today announced that Marc Dunoyer is to join the company in the newly created role of Executive Vice President, Global Portfolio & Product Strategy.
Thursday, 21 March 2013
AstraZeneca and Karolinska Institutet to create Integrated Translational Research Centre AstraZeneca and the Swedish medical university Karolinska Institutet announced today their intention to create an Integrated Translational Research Centre for cardiovascular and metabolic disease and regenerative medicine located at Karolinska Institutet’s site in Stockholm, Sweden.
Download our brochure

Download your comprehensive guide to partnering with us.


Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar